Dynamic assessment of CHADS-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients.

Introduction And Objectives: Stroke and bleeding risks in atrial fibrillation (AF) are often assessed at baseline to predict outcomes years later. We investigated whether dynamic changes in CHADS-VASc and HAS-BLED scores over time modify risk prediction.

Methods: We included patients with AF who were stable while taking vitamin K antagonists.

Anticoagulant therapy in patients with congenital FXI deficiency.

The bleeding phenotype of factor XI (FXI) deficiency is unpredictable. Bleeding is usually mild and mostly occurs after injury. Although FXI deficiency renders antithrombotic protection, some patients might eventually develop thrombosis or atrial fibrillation, requiring anticoagulant therapy.

Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.

Background: Polymorphisms in the vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) genes increase the bleeding risk in anticoagulated atrial fibrillation (AF) patients. Here, we aimed to investigate whether VKORC1 and CYP2C9 polymorphisms improved the predictive performance for major bleeding using the HAS-BLED score.

Material And Methods: We recruited 652 consecutive AF patients stable on vitamin K antagonist (INR 2.

Multicenter collaborative study for standardization of Candida albicans genotyping using a polymorphic microsatellite marker.

Microsatellite-based genotyping for Candida albicans can give discrepant results between laboratories when expressed in fragment sizes, because their determination depends on electrophoretic conditions. The interlaboratory reproducibility was assessed in six laboratories provided with an allelic ladder. Despite variations in size determinations, alleles were correctly assigned, making data transportable between laboratories.